化痰消瘀方加味治疗胃食管反流病伴慢性萎缩性胃炎的疗效观察

朱毅; 张丰田; 魏睦新

doi:10.3969/j.issn.1671-038X.2021.01.10

化痰消瘀方加味治疗胃食管反流病伴慢性萎缩性胃炎的疗效观察

- 1 南京医科大学第二附属医院老年科(南京, 210029);
- 2 南京医科大学第一附属医院中医科
基金项目:
江苏省中医药局科技基金项目(No:YB2015166)

详细信息

通讯作者: 魏睦新,E-mail:weimuxin@njmu.edu.cn

中图分类号: R573

收稿日期: 2020-07-30

Curative effect observation of modified Huatan Xiaoyu decoction on treatment of gastroesophageal reflux disease with chronic atrophic gastritis

- 1 Department of Geriatrics, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China;
- 2 Department of Traditional Chinese Medicine, the First Affiliated Hospital of Nanjing Medical University

More Information

Corresponding author: WEI Muxin, E-mail: weimuxin@njmu.edu.cn

Received Date: 30 July 2020

摘要

摘要: 目的:观察化痰消瘀方加味治疗胃食管反流病(GERD)伴慢性萎缩性胃炎(CAG)的疗效。方法:选取反流性食管炎(RE)或非糜烂性反流病(NERD)同时伴有CAG的70例患者为研究对象。按随机数字表法分为2组,每组各35例。对照组采用西医抑酸、促胃动力治疗,治疗组在对照组治疗基础上加用化痰消瘀方加味。治疗后观察比较2组患者的中医证候疗效、萎缩治疗总有效率、GERD治疗总有效率、汉密尔顿抑郁量表(HAMD)评分、汉密尔顿焦虑量表(HAMA)评分、匹兹堡睡眠质量指数(PSQI)评分。结果:疗程结束后,治疗组中医证候各项积分明显低于对照组(P<0.05);2组胃黏膜萎缩治疗总有效率分别为88.57%、65.71%,治疗组明显高于对照组(P<0.05);2组GERD治疗总有效率分别为82.86%、68.57%,治疗组明显高于对照组(P<0.05);2组HAMD、HAMA、PSQI评分较治疗前均降低(P<0.05),且治疗组积分明显低于对照组(P<0.05)。结论:化痰消瘀方加味治疗GERD伴CAG的疗效优于单纯使用常规西医治疗,值得临床推广。
- 化痰消瘀方 /
- 胃食管反流病 /
- 慢性萎缩性胃炎
Abstract: Objective: To observe the curative effect of modified Huatan Xiaoyu decoction in the treatment of gastroesophageal reflux disease(GERD) with chronic atrophic gastritis(CAG).Methods: Seventy cases either in the form of reflux esophagitis(RE) or non-erosive reflux disease(NERD), which were accompanied with CAG, were selected and randomly divided into 2 groups, each with 35 patients. In the control group, only western medicines were administered to suppress acid and promote gastric motility. In the treatment group, the same western medicine treatment was administered in combination with modified Huatan Xiaoyu decoction. After treatment, the traditional Chinese medicine(TCM) syndrome efficacy,total effective rate of atrophy treatment, total effective rate of anti-gastroesophageal reflux treatment, and scores as indicated in the Hamilton depression scale(HAMD), Hamilton anxiety scale(HAMA) and Pittsburgh sleep quality index(PSQI) were observed and compared between the groups.Results: After treatment, the itemized scores of TCM syndrome in the treatment group were significantly lower than that in the control group(P<0.05).The total effective rate of gastric mucosa atrophy in the two groups was 88.57% and 65.71%,respectively(P<0.05); the total effective rate of anti-gastroesophageal reflux treatment in the two groups was 82.86% and 68.57%, respectively(P<0.05). HAMD, HAMA and PSQI scores in both groups were lower than before treatment(P<0.05) while these scores in the treatment group were significantly lower than those in the control group, and the difference was statistically significant(P<0.05).Conclusion: In the treatment of GERD with CAG, the introduction of modified Huatan Xiaoyu decoction is more effective than conventional western medicine alone. It is worthy of clinical application and further investigation.
- Huatan Xiaoyu decoction /
- gastroesophageal reflux disease /
- chronic atrophic gastritis

HTML全文

参考文献(18)

[1]	李军祥,陈誩,吕宾,等.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.
[2]	Lahner E,Zagari RM,Zullo A,et al.Chronic atrophic gastritis:Natural history,diagnosis and therapeutic management.A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists[AIGO],the Italian Society of Digestive Endoscopy[SIED],the Italian Society of Gastroenterology[SIGE],and the Italian Society of Internal Medicine[SIMI][J].Dig Liver Dis,2019,51(12):1621-1632.
[3]	徐雪莲,魏睦新.胃癌前病变中医逆转的分期治疗进展[J].河北中医,2019,41(8):1271-1276,1280-1280.
[4]	中华中医药学会脾胃病分会.胃食管反流病中医诊疗专家共识意见(2017)[J].中国中西医结合消化杂志,2017,25(5):321-326.
[5]	Li SW,Huang MF,Wu GJ,et al.Efficacy of Chinese Herbal Formula Sini Zuojin Decoction in Treating Gastroesophageal Reflux Disease:Clinical Evidence and Potential Mechanisms[J].Front Pharmacol,2020,11:76.
[6]	范尧夫,吴燕敏,刘皓,等.中国华东地区人群胃癌癌前病变发病相关危险因素分析[J].胃肠病学和肝病学杂志,2014,23(2):143-146.
[7]	刘皓,吕涛,王岚,等.化痰消瘀方治疗慢性萎缩性胃炎伴胆汁反流的临床疗效及对胃肠激素和炎症、氧化应激相关因子水平的影响[J].河北中医,2019,41(3):352-356.
[8]	邹多武.2014年中国胃食管反流病专家共识意见解读[J].中华胃食管反流病电子杂志,2015,(1):4-5.
[9]	中华医学会消化病学分会.中国慢性胃炎共识意见(2017年,上海)[J].胃肠病学,2017,22(11):670-687.
[10]	魏睦新,王平.胃肠动力中药的基础与临床[M].北京:化学工业出版社生物·医药出版分社.2010:227-230.
[11]	魏睦新,冷秀梅.中西医结合诊治胃癌前病变基础与临床[M].南京:东南大学出版社.2018:21-25.
[12]	王广欣,丰义宽.氟哌噻吨美利曲辛片辅助治疗难治性非糜烂性胃食管反流病的疗效及安全性[J].实用临床医药杂志,2018,22(11):36-40.
[13]	胡祥鹏,张深深,王乔,等.胃食管反流病重叠消化不良的临床及精神心理特征研究[J].中华全科医学,2019,17(9):1447-1449,1550-1550.
[14]	Bonavina L,Fisichella PM,Gavini S,et al.Clinical course of gastroesophageal reflux disease and impact of treatment in symptomatic young patients[J].Ann N Y Acad Sci,2020, 1481(1):117-126.
[15]	胃食管反流病外科诊疗共识(2019版)[J].中华胃食管反流病电子杂志,2019,6(1):3-9.
[16]	中国医疗保健国际交流促进会胃食管反流多学科分会.中国胃食管反流病多学科诊疗共识[J].中国医学前沿杂志(电子版),2019,11(9):30-56.
[17]	冯彦.丹参的现代药理研究及临床应用[J].中医临床研究,2017,9(30):46-47.
[18]	褚璨灿,师为人,陈云志,等.左金丸临床应用与实验研究进展[J].实用中医药杂志,2019,35(5):626-629.